Cytokine therapy with interleukin-2/anti-interleukin-2 monoclonal antibody complexes expands CD4+CD25+Foxp3+ regulatory T cells and attenuates development and progression of atherosclerosis

Circulation

Volumn 126, Issue 10, 2012, Pages 1256-1266

  Dinh, Tam Nguyen ^a   Kyaw, Tin Soe ^a,b   Kanellakis, Peter ^a   To, Kelly ^a   Tipping, Peter ^b   Toh, Ban Hock ^b   Bobik, Alexander ^a   Agrotis, Alex ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

atherosclerosis; cytokines; inflammation

Indexed keywords

APOLIPOPROTEIN E; CD83 ANTIGEN; CYCLINE; INTERLEUKIN 18; INTERLEUKIN 18BETA; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY JES6 1; MONOCYTE CHEMOTACTIC PROTEIN 1; RECOMBINANT INTERLEUKIN 2; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE COURSE; DRUG BLOOD LEVEL; INFLAMMATION; LIPID DIET; LIVER; LYMPH NODE; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN; SPLEEN CELL; TH1 CELL; TH17 CELL; TH2 CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, CD4; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CELL DIVISION; DIETARY FATS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FORKHEAD TRANSCRIPTION FACTORS; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MICE; MICE, MUTANT STRAINS; T-LYMPHOCYTES, REGULATORY;

EID: 84865865387     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.099044     Document Type: Article

References (41)

1. Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: Lessons from mouse models. Nat Rev Immunol. 2008;8:802-815.
2. Zhou X, Stemme S, Hansson GK. Evidence for a local immune response in atherosclerosis. CD4-T cells infiltrate lesions of apolipoprotein-Edeficient mice. Am J Pathol. 1996;149:359-366.
3. de Boer OJ, van der Wal AC, Verhagen CE, Becker AE. Cytokine secretion profiles of cloned T cells from human aortic atherosclerotic plaques. J Pathol. 1999;188:174-179.
4. Zhou X, Nicoletti A, Elhage R, Hansson GK. Transfer of CD4-T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation. 2000;102:2919-2922.
5. Eid RE, Rao DA, Zhou J, Lo SF, Ranjbaran H, Gallo A, Sokol SI, Pfau S, Pober JS, Tellides G. Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation. 2009; 119:1424-1432.
6. de Boer OJ, van der Meer JJ, Teeling P, van der Loos CM, van der Wal AC. Low numbers of Foxp3 positive regulatory T cells are present in all developmental stages of human atherosclerotic lesions. Plos One. 2007; 2:e779.
7. Ait-Oufella H, Salomon BL, Potteaux S, Robertson AK, Gourdy P, Zoll J, Merval R, Esposito B, Cohen JL, Fisson S, Flavell RA, Hansson GK, Klatzmann D, Tedgui A, Mallat Z. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med. 2006;12:178-180.
8. Nakamura K, Kiaani A, Strober W. Cell contact-dependent immunosuppression by CD4(-)CD25(-) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med. 2001;194: 629-644.
9. Ito T, Hanabuchi S, Wang YH, Park WR, Arima K, Bover L, Qin FX, Gilliet M, Liu YJ. Two functional subsets of Foxp3-regulatory T cells in human thymus and periphery. Immunity. 2008;28:870-880.
10. Lin J, Li M, Wang Z, He S, Ma X, Li D. The role of CD4-CD25-regulatory T cells in macrophage-derived foam-cell formation. J Lipid Res. 2010;51:1208-1217.
11. Riley JL, June CH, Blazar BR. Human T regulatory cell therapy: Take a billion or so and call me in the morning. Immunity. 2009;30:656-665.
12. Yang K, Li D, Luo M, Hu Y. Generation of HSP60-specific regulatory T cell and effect on atherosclerosis. Cell Immunol. 2006;243:90-95.
13. Klingenberg R, Lebens M, Hermansson A, Fredrikson GN, Strodthoff D, Rudling M, Ketelhuth DF, Gerdes N, Holmgren J, Nilsson J, Hansson GK. Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis. Arterioscler Thromb Vasc Biol. 2010;30:946-952.
14. Sasaki N, Yamashita T, Takeda M, Shinohara M, Nakajima K, Tawa H, Usui T, Hirata K. Oral anti-CD3 antibody treatment induces regulatory T cells and inhibits the development of atherosclerosis in mice. Circulation. 2009;120:1996-2005.
15. van Puijvelde GH, Hauer AD, de Vos P, van den Heuvel R, van Herwijnen MJ, van der Zee R, van Eden W, van Berkel TJ, Kuiper J. Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis. Circulation. 2006;114:1968-1976.
16. Gaffen SL, Liu KD. Overview of interleukin-2 function, production and clinical applications. Cytokine. 2004;28:109-123.
17. Finkelman FD, Madden KB, Morris SC, Holmes JM, Boiani N, Katona IM, Maliszewski CR. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J Immunol. 1993;151: 1235-1244.
18. Webster KE, Walters S, Kohler RE, Mrkvan T, Boyman O, Surh CD, Grey ST, Sprent J. In vivo expansion of T reg cells with IL-2-mab complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J Exp Med. 2009;206: 751-760.
19. Tomala J, Chmelova H, Mrkvan T, Blanka R, Kovar M. In vivo expansion of activated naive CD8-T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy. J Immunol. 2009;183:4904-4912.
20. Scheffold A, Huhn J, Hofer T. Regulation of CD4-CD25-regulatory T cell activity: it takes (IL-)two to tango. Eur J Immunol. 2005;35: 1336-1341.
21. Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, Hipkiss EL, Ravi S, Kowalski J, Levitsky HI, Powell JD, Pardoll DM, Drake CG, Vignali DA. Role of Lag-3 in regulatory T cells. Immunity. 2004;21: 503-513.
22. Strauss L, Bergmann C, Szczepanski MJ, Lang S, Kirkwood JM, Whiteside TL. Expression of ICOS on human melanoma-infiltrating CD4-CD25highFoxp3-T regulatory cells: implications and impact on tumor-mediated immune suppression. J Immunol. 2008;180:2967-2980.
23. Ermann J, Hoffmann P, Edinger M, Dutt S, Blankenberg FG, Higgins JP, Negrin RS, Fathman CG, Strober S. Only the CD62L-subpopulation of CD4-CD25-regulatory T cells protects from lethal acute GVHD. Blood. 2005;105:2220-2226.
24. Prechtel AT, Turza NM, Theodoridis AA, Steinkasserer A. CD83 knockdown in monocyte-derived dendritic cells by small interfering RNA leads to a diminished T cell stimulation. J Immunol. 2007;178: 5454-5464.
25. Setoguchi R, Hori S, Takahashi T, Sakaguchi S. Homeostatic maintenance of natural Foxp3(-) CD25(-) CD4(-) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med. 2005;201:723-735.
26. Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science. 2006;311:1924-1927.
27. Letourneau S, van Leeuwen EM, Krieg C, Martin C, Pantaleo G, Sprent J, Surh CD, Boyman O. IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25. Proc Natl Acad Sci USA. 2010;107:2171-2176.
28. Zhou X, Robertson AK, Rudling M, Parini P, Hansson GK. Lesion development and response to immunization reveal a complex role for CD4 in atherosclerosis. Circ Res. 2005;96:427-434.
29. Piccirillo CA, Shevach EM. Cutting edge: Control of CD8-T cell activation by CD4-CD25-immunoregulatory cells. J Immunol. 2001; 167:1137-1140.
30. Hua J, Liang S, Ma X, Webb TJ, Potter JP, Li Z. The interaction between regulatory T cells and NKT cells in the liver: A CD1d bridge links innate and adaptive immunity. PLoS One. 2011;6:e27038.
31. Buono C, Come CE, Stavrakis G, Maguire GF, Connelly PW, Lichtman AH. Influence of interferon-gamma on the extent and phenotype of diet-induced atherosclerosis in the LDLR-deficient mouse. Arterioscler Thromb Vasc Biol. 2003;23:454-460.
32. Davenport P, Tipping PG. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol. 2003;163:1117-1125.
33. Xu D, Liu H, Komai-Koma M, Campbell C, McSharry C, Alexander J, Liew FY. CD4-CD25-regulatory T cells suppress differentiation and functions of Th1 and Th2 cells, leishmania major infection, and colitis in mice. J Immunol. 2003;170:394-399.
34. Zhou X, Paulsson G, Stemme S, Hansson GK. Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apoE-knockout mice. J Clin Invest. 1998;101: 1717-1725.
35. Shevach EM. Mechanisms of Foxp3-T regulatory cell-mediated suppression. Immunity. 2009;30:636-645.
36. Mandapathil M, Hilldorfer B, Szczepanski MJ, Czystowska M, Szajnik M, Ren J, Lang S, Jackson EK, Gorelik E, Whiteside TL. Generation and accumulation of immunosuppressive adenosine by human CD4-CD25 highFoxp3-regulatory T cells. J Biol Chem. 2010;285:7176-7186.
37. von Allmen CE, Schmitz N, Bauer M, Hinton HJ, Kurrer MO, Buser RB, Gwerder M, Muntwiler S, Sparwasser T, Beerli RR, Bachmann MF. Secretory phospholipase A2-IId is an effector molecule of CD4-CD25-regulatory T cells. Proc Natl Acad Sci USA. 2009;106:11673-11678.
38. Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4-CD25-Foxp3- regulatory T cells induce cytokine deprivationmediated apoptosis of effector CD4-T cells. Nat Immunol. 2007;8: 1353-1362.
39. Gosling J, Slaymaker S, Gu L, Tseng S, Zlot CH, Young SG, Rollins BJ, Charo IF. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest. 1999;103:773-778.
40. Bayry J, Triebel F, Kaveri SV, Tough DF. Human dendritic cells acquire a semimature phenotype and lymph node homing potential through interaction with CD4-CD25-regulatory T cells. J Immunol. 2007;178:4184-4193.
41. Weber C, Meiller S, Doring Y, Koch M, Drechsler M, Megens RTA, Rowinska Z, Bidzhekov K, Fecher C, Ribechini E, van Zandvoort MAMJ, Binder CJ, Jelinek I, Hristov M, Boon L, Jung S, Korn T, Lutz MB, Forster I, Zenke M, Hieronymus T, Junt T, Zernecke A. CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice. J Clin Invest. 2011;121:2898-2910.